PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31

PTC THERAPEUTICS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026

$61.53+2.29 (+3.87%)

Close on Oct 19, 2026

Market cap: $5.66B
P/E (TTM): –
Dividend yield: –

PTC THERAPEUTICS, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31
Revenue	1,731	807	938	699	539	381	307	265	194	83	37	25	35	34	105
Cost of Revenue	–	–	–	–	–	–	12	13	4.58	0	0	–	–	–	–
Gross Profit	–	–	–	–	–	–	295	252	190	83	37	–	–	–	–
Research & Development	455	534	667	651	541	478	257	172	117	118	122	80	55	46	59
Selling, General & Admin	347	301	333	326	286	245	203	154	121	97	–	–	–	–	–
General & Administrative	–	–	–	–	–	–	–	–	121	97	82	45	25	15	16
Operating Expenses	864	1,109	1,377	1,146	913	813	548	380	259	215	204	125	80	61	75
Operating Income	867	-303	-440	-447	-374	-432	-241	-116	-64	-132	-167	-99	-45	-27	31
Other Non-Operating Income	-18	6.54	10	-49	-58	85	14	0.13	-1.28	-1.21	-0.47	-0.21	0.04	1.78	0.46
Merger & Restructuring Charges	–	–	–	–	–	–	–	–	0	–	–	–	–	–	–
Asset Impairment Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	–	–
Gain (Loss) on Investments	–	–	–	–	0.80	0.70	0	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	-0.13	-4.30	-0.81	-0.08	–	-0.02	-0.31	0.00	-0.01	0	0.04	0	–	–	–
Pretax Income	697	-363	-696	-587	-518	-403	-240	-128	-78	-142	-170	-98	-52	-26	29
Income Tax Expense	14	0.18	-70	-28	5.56	35	12	-0.03	1.34	0.57	0.49	-4.69	–	–	-2.31
Net Income incl. Noncontrolling Interests	–	–	–	–	–	–	–	–	–	-142	-170	-94	-66	133	31
Net Income	683	-363	-627	-559	-524	-438	-252	-128	-79	-142	-170	-94	-52	-26	31
Net Income to Common	683	-363	-627	-559	-524	-438	-252	-128	–	–	-170	-94	-66	0.73	0.03
EPS (Basic)(per share)	8.58	-4.73	-8.37	-7.79	-7.43	-6.64	-4.27	-2.75	-2.02	-4.17	-5.07	-2.97	-5.18	219.76	23.95
EPS (Diluted)(per share)	7.78	-4.73	-8.37	-7.79	-7.43	-6.64	-4.27	-2.75	-2.02	-4.17	-5.07	-2.97	-5.18	42.50	4.55
Shares Outstanding (Basic, Weighted)(shares)	80	77	75	72	70	66	59	47	39	34	34	32	13	0.00	0.00
Shares Outstanding (Diluted, Weighted)(shares)	88	77	75	72	70	66	59	47	39	34	34	32	13	0.02	0.01
EBITDA	906	-227	-203	-319	-310	-388	-209	-90	-47	-129	-164	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: 12.5%
Net margin: -3.8%
Return on equity, FY2025: -104.7%

Financial strength

Current ratio: 3.39
Debt to equity: -3.57
Debt to assets: 18.2%
Cash to current liabilities: 136.2%

Valuation

P/E ratio: –
Price to sales: 5.61
Price to book: –
Dividend yield: –